UBS Asset Management Americas Inc. cut its holdings in Five Prime Therapeutics Inc (NASDAQ:FPRX) by 10.1% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 96,858 shares of the biotechnology company’s stock after selling 10,832 shares during the period. UBS Asset Management Americas Inc. owned about 0.28% of Five Prime Therapeutics worth $2,123,000 as of its most recent SEC filing.
Other institutional investors have also added to or reduced their stakes in the company. Teacher Retirement System of Texas purchased a new stake in shares of Five Prime Therapeutics in the 4th quarter worth about $221,000. Oppenheimer & Co. Inc. purchased a new stake in shares of Five Prime Therapeutics in the 3rd quarter worth about $223,000. Fox Run Management L.L.C. purchased a new stake in shares of Five Prime Therapeutics in the 4th quarter worth about $386,000. Ark Investment Management LLC boosted its position in shares of Five Prime Therapeutics by 299.2% in the 2nd quarter. Ark Investment Management LLC now owns 14,174 shares of the biotechnology company’s stock worth $427,000 after buying an additional 10,623 shares in the last quarter. Finally, Franklin Street Advisors Inc. NC purchased a new stake in shares of Five Prime Therapeutics in the 4th quarter worth about $548,000. Institutional investors and hedge funds own 74.88% of the company’s stock.
Shares of Five Prime Therapeutics stock opened at $16.12 on Monday. Five Prime Therapeutics Inc has a 1 year low of $15.82 and a 1 year high of $48.87.
Several equities research analysts recently commented on the stock. BidaskClub lowered shares of Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 9th. Zacks Investment Research lowered shares of Five Prime Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, January 25th. ValuEngine lowered shares of Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. BMO Capital Markets cut their price objective on shares of Five Prime Therapeutics from $75.00 to $60.00 and set an “outperform” rating on the stock in a report on Wednesday, February 28th. Finally, Nomura cut their price objective on shares of Five Prime Therapeutics from $94.00 to $25.00 and set a “buy” rating on the stock in a report on Wednesday, February 28th. Three analysts have rated the stock with a sell rating and five have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $47.20.
Five Prime Therapeutics Profile
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.